Jump to content

Stuart Schreiber

From Wikipedia, the free encyclopedia
(Redirected from Stuart L. Schreiber)
Stuart L. Schreiber
Born (1956-02-06) February 6, 1956 (age 68)
Alma materUniversity of Virginia
Harvard University
Known forOrganic Synthesis
Chemical Biology
Human Biology
Therapeutics Discovery
AwardsArthur C. Cope Award (2015)
Wolf Prize (2016)
Scientific career
FieldsChemical Biology
InstitutionsYale University
Harvard University
Broad Institute
ThesisI: Oxidation of tertiary amines / II: Peroxides in organic synthesis (1981)
Doctoral advisorRobert Burns Woodward
Yoshito Kishi

Stuart Schreiber is an American chemist who is the Morris Loeb Research Professor at Harvard University,[1] a co-Founder of the Broad Institute,[2] Howard Hughes Medical Institute Investigator, Emeritus,[3] and a member of the National Academy of Sciences[4] and National Academy of Medicine.[5] He currently leads Arena BioWorks.

His work integrates chemical biology and human biology to advance the science of therapeutics. Key advances include the discovery that small molecules can function as “molecular glues” that promote protein–protein interactions, the co-discovery of mTOR and its role in nutrient-response signaling, the discovery of histone deacetylases and (with Michael Grunstein and David Allis) the demonstration that chromatin marks regulate gene expression, the development and application of diversity-oriented synthesis to microbial therapeutics, and the discovery of vulnerabilities of cancer cells linked to genetic, lineage and cell-state features, including ferroptotic vulnerabilities. His awards include the Wolf Prize in Chemistry and the Arthur Cope Award. His approach to discovering new therapeutics guided many biotechnology companies that he founded, including Vertex Pharmaceuticals and Ariad Pharmaceuticals. He has founded or co-founded 14 biotechnology companies, which have developed 16 first-in-human approved drugs or advanced clinical candidates.

Early life

[edit]

Schreiber was born on February 6, 1956, in Eatontown, NJ to Mary Geraldine Schreiber and Lieutenant Colonel Thomas Sewell Schreiber. From the ages of one to four he lived in a small village in France—Villennes-sur-Seine, with his family, where his father was a battalion commander at Supreme Headquarters Allied Powers Europe.[6] Shortly after returning to New Jersey, they moved to Fairfax, VA, where Tom Schreiber worked as an applied mathematician and physicist at Signal Corp on Fort Monmouth. At age 61, Schreiber discovered that Tom Schreiber was not his biological father.[7]

Schreiber attended Luther Jackson Junior High School in Falls Church, VA and graduated from Oakton High School in Fairfax, VA in 1973 after completing a 3-year work study program that prepared him for work in the construction field.[8] He did not take a chemistry class in high school.

Education and training

[edit]

Schreiber obtained a Bachelor of Science degree in chemistry from the University of Virginia in 1977, after which he entered Harvard University as a graduate student in chemistry. He joined the research group of Robert B. Woodward and after Woodward's death continued his studies under the supervision of Yoshito Kishi. In 1980, he joined the faculty of Yale University as an assistant professor in chemistry, and in 1988 he moved to Harvard University as the Morris Loeb Professor.[9]

Career

[edit]

Schreiber started his research work in organic synthesis, focusing on concepts such as the use of [2 + 2] photocycloadditions to establish stereochemistry in complex molecules, the fragmentation of hydroperoxides to produce macrolides, ancillary stereocontrol, group selectivity and two-directional synthesis. Notable accomplishments include the total syntheses of complex natural products such as periplanone B, talaromycin B, asteltoxin, avenaciolide, gloeosporone, hikizimicin, mycoticin A, epoxydictymene[10] and the immunosuppressant FK-506.[citation needed]

Following his work on the FK506-binding protein FKBP12 in 1988, Schreiber reported that the small molecules FK506 and cyclosporin inhibit the activity of the phosphatase calcineurin by forming the ternary complexes FKBP12-FK506-calcineurin and cyclophilin-ciclosporin-calcineurin.[11] This work, together with work by Gerald Crabtree at Stanford University concerning the NFAT proteins, led to the elucidation of the calcium-calcineurin-NFAT signaling pathway.[12] The Ras-Raf-MAPK pathway was not elucidated for another year.[citation needed]

In 1993, Schreiber and Crabtree developed bifunctional molecules or “chemical inducers of proximity” (CIPs), which provide small-molecule activation over numerous signaling molecules and pathways (e.g., the Fas, insulin, TGFβ and T-cell receptors[13][14]) through proximity effects. Schreiber and Crabtree demonstrated that small molecules could activate a signaling pathway in an animal with temporal and spatial control.[15] Dimerizer kits have been distributed freely resulting in many peer-reviewed publications. Its promise in gene therapy has been highlighted by the ability of a small molecule to activate a small-molecule regulated EPO receptor and to induce erythropoiesis (Ariad Pharmaceuticals, Inc.), and more recently in human clinical trials for treatment of graft-vs-host disease.[16]

In 1994, Schreiber and co-workers investigated (independently with David Sabitini) the master regulator of nutrient sensing, mTOR. They found that the small molecule rapamycin simultaneously binds FKBP12 and mTOR (originally named FKBP12-rapamycin binding protein, FRAP).[17] Using diversity-oriented synthesis and small-molecule screening, Schreiber illuminated the nutrient-response signaling network involving TOR proteins in yeast and mTOR in mammalian cells. Small molecules such as uretupamine[18] and rapamycin were shown to be particularly effective in revealing the ability of proteins such as mTOR, Tor1p, Tor2p, and Ure2p to receive multiple inputs and to process them appropriately towards multiple outputs (in analogy to multi-channel processors). Several pharmaceutical companies are now targeting the nutrient-signaling network for the treatment of several forms of cancer, including solid tumors.[19]

In 1995, Schreiber and co-workers found that the small molecule lactacystin binds and inhibits specific catalytic subunits of the proteasome,[20] a protein complex responsible for the bulk of proteolysis in the cell, as well as proteolytic activation of certain protein substrates. As a non-peptidic proteasome inhibitor lactacysin has proven useful in the study of proteasome function. Lactacystin modifies the amino-terminal threonine of specific proteasome subunits. This work helped to establish the proteasome as a mechanistically novel class of protease: an amino-terminal threonine protease. The work led to the use of bortezomib to treat multiple myeloma.[citation needed]

In 1996, Schreiber and co-workers used the small molecules trapoxin and depudecin to investigate the histone deacetylases (HDACs).[21] Prior to Schreiber's work in this area, the HDAC proteins had not been isolated. Coincident with the HDAC work, David Allis and colleagues reported work on the histone acetyltransferases (HATs). These two contributions catalyzed much research in this area, eventually leading to the characterization of numerous histone-modifying enzymes, their resulting histone “marks”, and numerous proteins that bind to these marks. By taking a global approach to understanding chromatin function, Schreiber proposed a “signaling network model” of chromatin and compared it to an alternative view, the “histone code hypothesis” presented by Strahl and Allis.[22] These studies shined a bright light on chromatin as a key gene expression regulatory element rather than simply a structural element used for DNA compaction.[citation needed]

Diversity-oriented synthesis

[edit]

Schreiber applied small molecules to biology through the development of diversity-oriented synthesis (DOS),[23] chemical genetics,[24] and ChemBank.[25] Schreiber has shown that DOS can produce small molecules distributed in defined ways in chemical space by virtue of their different skeletons and stereochemistry, and that it can provide chemical handles on products anticipating the need for follow-up chemistry using, for example, combinatorial synthesis and the so-called Build/Couple/Pair strategy of modular chemical synthesis. DOS pathways and new techniques for small-molecule screening [26][27][28] provided many new, potentially disruptive insights into biology. Small-molecule probes of histone and tubulin deacetylases, transcription factors, cytoplasmic anchoring proteins, developmental signaling proteins (e.g., histacin, tubacin, haptamide, uretupamine, concentramide, and calmodulophilin), among many others, have been uncovered in the Schreiber lab using diversity-oriented synthesis and chemical genetics. Multidimensional screening was introduced in 2002 and has provided insights into tumorigenesis, cell polarity, and chemical space, among others.[29]

Using diversity-oriented synthesis, the Schreiber Lab and collaborators discovered numerous novel antimicrobial compounds including the bicyclic azetidine BRD7929 that could both cure and prevent the transmission of malaria in mice, targeting multiple steps in the life cycle of Plasmodium falciparum.[30][31] They found another synthetic azetidine derivative, BRD4592, which kills Mycobacterium tuberculosis through allosteric inhibition of its tryptophan synthase.[32] High throughput screens further uncovered compounds that inhibit replication of Trypanosoma cruzi[33] and Hepatitis C virus,[34][35] and inhibit Toxoplasma gondii growth.[36]

Other research

[edit]

Schreiber also contributed to more conventional small molecule discovery projects. He collaborated with Tim Mitchison to discover monastrol – the first small-molecule inhibitor of mitosis that does not target tubulin.[37] Monastrol was shown to inhibit kinesin-5, a motor protein and was used to gain new insights into the functions of kinesin-5. This work led pharmaceutical company Merck, among others, to pursue anti-cancer drugs that target human kinesin-5.[citation needed]

Recently[when?] the Schreiber Lab discovered that when certain aggressive cancer cells become resistant to drug treatments, they also become vulnerable to ferroptosis—a natural cellular self-destruction mechanism triggered by peroxide and iron ions undergoing the Fenton reaction. Free radicals unleash a chain reaction turning normal lipids in the cell membrane into toxic radical species. They found that drug-resistant cancer cells that have acquired this new vulnerability rely on an enzyme called GPX4 for survival. GPX4 stops the chain reaction leading to ferroptosis by converting the dangerous lipid peroxides to benign alcohols. They further showed that a small molecule inhibitor of GPX4 kills cancer cells by increasing their vulnerability to ferroptosis.[38]

Impact on chemical biology

[edit]

Schreiber has used small molecules to study three specific areas of biology, and then through the more general application of small molecules in biomedical research. Academic screening centers have been created that emulate the Harvard Institute of Chemistry and Cell Biology and the Broad Institute; in the U.S., there has been a nationwide effort to expand this capability via the government-sponsored NIH Road Map. Chemistry departments have changed their names to include the term chemical biology and new journals have been introduced (Cell Chemical Biology, ChemBioChem, Nature Chemical Biology, ACS Chemical Biology]) to cover the field. Schreiber has been involved in the founding of numerous biopharmaceutical companies whose research relies on chemical biology: Vertex Pharmaceuticals, Inc. (VRTX), Ariad Pharmaceuticals, Inc. (ARIA), Infinity Pharmaceuticals, Inc (INFI), Forma Therapeutics, H3 Biomedicine, Jnana Therapeutics, and Kojin Therapeutics. These companies have produced new therapeutics in several disease areas, including cystic fibrosis and cancer.[39]

Selected awards

[edit]

Notes and references

[edit]
  1. ^ "Stuart L. Schreiber". chemistry.harvard.edu. Retrieved 2023-11-29.
  2. ^ "Stuart L. Schreiber". Broad Institute. 2015-11-23. Retrieved 2023-11-29.
  3. ^ "Stuart L. Schreiber, PhD | Investigator Emeriti Profile | 1994-2018 | HHMI". www.hhmi.org. Retrieved 2023-11-29.
  4. ^ "Stuart L. Schreiber". www.nasonline.org. Retrieved 2023-11-29.
  5. ^ "The National Academy of Medicine honors Stuart Schreiber". chemistry.harvard.edu. Retrieved 2023-11-29.
  6. ^ "Find an object | Imperial War Museums". www.iwm.org.uk. Retrieved 2023-11-29.
  7. ^ Schreiber, Stuart L. (July–August 2019). "Truth: A Love Story". Harvard Magazine. Retrieved November 29, 2023.
  8. ^ Werth, Barry (1994). The Billion Dollar Molecule: One Company's quest for the perfect drug. United States of America: Simon & Schuster. pp. 197–198. ISBN 978-0671510572.
  9. ^ "Department of Chemistry". chemistry.as.virginia.edu. Retrieved 2023-11-16.
  10. ^ Jamison, Timothy F.; Shambayati, Soroosh; Crowe, William E.; Schreiber, Stuart L. (1994-06-01). "Cobalt-Mediated Total Synthesis of (+)-Epoxydictymene". Journal of the American Chemical Society. 116 (12): 5505–5506. doi:10.1021/ja00091a079. ISSN 0002-7863.
  11. ^ Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (August 1991). "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes". Cell. 66 (4): 807–15. doi:10.1016/0092-8674(91)90124-H. PMID 1715244. S2CID 22094672.
  12. ^ Schreiber SL, Crabtree GR (1995). "Immunophilins, ligands, and the control of signal transduction". Harvey Lectures. 91: 99–114. PMID 9127988.
  13. ^ Yang J, Symes K, Mercola M, Schreiber SL (January 1998). "Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment". Current Biology. 8 (1): 11–8. Bibcode:1998CBio....8...11Y. doi:10.1016/S0960-9822(98)70015-6. PMID 9427627. S2CID 18682114.
  14. ^ Stockwell BR, Schreiber SL (June 1998). "Probing the role of homomeric and heteromeric receptor interactions in TGF-beta signaling using small molecule dimerizers". Current Biology. 8 (13): 761–70. Bibcode:1998CBio....8..761S. doi:10.1016/S0960-9822(98)70299-4. PMID 9651680. S2CID 93779.
  15. ^ "Functional Analysis of Fas Signaling in vivo Using Synthetic Dimerizers" David Spencer, Pete Belshaw, Lei Chen, Steffan Ho, Filippo Randazzo, Gerald R. Crabtree, Stuart L. Schreiber Curr. Biol. 1996, 6, 839–848.
  16. ^ Di Stasi, Antonio; Tey, Siok-Keen; Dotti, Gianpietro; Fujita, Yuriko; Kennedy-Nasser, Alana; Martinez, Caridad; Straathof, Karin; Liu, Enli; Durett, April G. (2011-11-03). "Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy". New England Journal of Medicine. 365 (18): 1673–1683. doi:10.1056/nejmoa1106152. ISSN 0028-4793. PMC 3236370. PMID 22047558.
  17. ^ Brown EJ, Albers MW, Shin TB, et al. (June 1994). "A mammalian protein targeted by G1-arresting rapamycin-receptor complex". Nature. 369 (6483): 756–8. Bibcode:1994Natur.369..756B. doi:10.1038/369756a0. PMID 8008069. S2CID 4359651.
  18. ^ "Dissection of a glucose-sensitive pathway of the nutrient-response network using diversity-oriented synthesis and small molecule microarrays" Finny G. Kuruvilla, Alykhan F. Shamji, Scott M. Sternson, Paul J. Hergenrother, Stuart L. Schreiber, Nature, 2002, 416, 653–656.
  19. ^ Shamji AF, Nghiem P, Schreiber SL (August 2003). "Integration of growth factor and nutrient signaling: implications for cancer biology". Molecular Cell. 12 (2): 271–80. doi:10.1016/j.molcel.2003.08.016. PMID 14536067.
  20. ^ Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL (1995). "Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin". Science. 268 (5211): 726–31. Bibcode:1995Sci...268..726F. doi:10.1126/science.7732382. PMID 7732382. S2CID 37779687.
  21. ^ Taunton J, Hassig CA, Schreiber SL (April 1996). "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p". Science. 272 (5260): 408–11. Bibcode:1996Sci...272..408T. doi:10.1126/science.272.5260.408. PMID 8602529. S2CID 25717734.
  22. ^ Schreiber SL, Bernstein BE (December 2002). "Signaling network model of chromatin". Cell. 111 (6): 771–8. doi:10.1016/S0092-8674(02)01196-0. PMID 12526804. S2CID 8824652.
  23. ^ (a) Schreiber SL (March 2000). "Target-oriented and diversity-oriented organic synthesis in drug discovery". Science. 287 (5460): 1964–9. Bibcode:2000Sci...287.1964S. doi:10.1126/science.287.5460.1964. PMID 10720315. S2CID 42413249. (b) Burke MD, Berger EM, Schreiber SL (October 2003). "Generating diverse skeletons of small molecules combinatorially". Science. 302 (5645): 613–8. Bibcode:2003Sci...302..613B. doi:10.1126/science.1089946. PMID 14576427. S2CID 6168881. (c) Burke MD, Schreiber SL (January 2004). "A planning strategy for diversity-oriented synthesis". Angewandte Chemie. 43 (1): 46–58. doi:10.1002/anie.200300626. PMID 14694470.
  24. ^ "The small-molecule approach to biology: Chemical genetics and diversity-oriented organic synthesis make possible the systematic exploration of biology”, S L Schreiber, C&E News, 2003, 81, 51–61.
  25. ^ Strausberg RL, Schreiber SL (April 2003). "From knowing to controlling: a path from genomics to drugs using small molecule probes". Science. 300 (5617): 294–5. Bibcode:2003Sci...300..294S. doi:10.1126/science.1083395. PMID 12690189. S2CID 39877841.
  26. ^ Stockwell BR, Haggarty SJ, Schreiber SL (February 1999). "High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications". Chemistry & Biology. 6 (2): 71–83. doi:10.1016/S1074-5521(99)80004-0. PMID 10021420.
  27. ^ "Printing Small Molecules as Microarrays and Detecting Protein-Ligand Interactions en Masse" Gavin MacBeath, Angela N. Koehler, Stuart L. Schreiber J. Am. Chem. Soc. 1999, 121, 7967–7968.
  28. ^ MacBeath G, Schreiber SL (September 2000). "Printing proteins as microarrays for high-throughput function determination". Science. 289 (5485): 1760–3. Bibcode:2000Sci...289.1760M. doi:10.1126/science.289.5485.1760. PMID 10976071. S2CID 27553611.
  29. ^ Schreiber SL (July 2005). "Small molecules: the missing link in the central dogma". Nature Chemical Biology. 1 (2): 64–6. doi:10.1038/nchembio0705-64. PMID 16407997. S2CID 14399359.
  30. ^ Kato, Nobutaka; Comer, Eamon; Sakata-Kato, Tomoyo; Sharma, Arvind; Sharma, Manmohan; Maetani, Micah; Bastien, Jessica; Brancucci, Nicolas M.; Bittker, Joshua A.; Corey, Victoria; Clarke, David; Derbyshire, Emily R.; Dornan, Gillian L.; Duffy, Sandra; Eckley, Sean (2016-10-20). "Diversity-oriented synthesis yields novel multistage antimalarial inhibitors". Nature. 538 (7625): 344–349. Bibcode:2016Natur.538..344K. doi:10.1038/nature19804. ISSN 1476-4687. PMC 5515376. PMID 27602946.
  31. ^ Sharma, Manmohan; Mutharasappan, Nachiappan; Manickam, Yogavel; Harlos, Karl; Melillo, Bruno; Comer, Eamon; Tabassum, Heena; Parvez, Suhel; Schreiber, Stuart L.; Sharma, Amit (2022-07-07). "Inhibition of Plasmodium falciparum phenylalanine tRNA synthetase provides opportunity for antimalarial drug development". Structure. 30 (7): 962–972.e3. doi:10.1016/j.str.2022.03.017. ISSN 1878-4186. PMID 35460612.
  32. ^ Wellington, Samantha; Nag, Partha P.; Michalska, Karolina; Johnston, Stephen E.; Jedrzejczak, Robert P.; Kaushik, Virendar K.; Clatworthy, Anne E.; Siddiqi, Noman; McCarren, Patrick; Bajrami, Besnik; Maltseva, Natalia I.; Combs, Senya; Fisher, Stewart L.; Joachimiak, Andrzej; Schreiber, Stuart L. (September 2017). "A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase". Nature Chemical Biology. 13 (9): 943–950. doi:10.1038/nchembio.2420. ISSN 1552-4469. PMC 6886523. PMID 28671682.
  33. ^ Germain, Andrew R.; Carmody, Leigh C.; Dockendorff, Chris; Galan-Rodriguez, Cristina; Rodriguez, Ana; Johnston, Stephen; Bittker, Joshua A.; MacPherson, Lawrence; Dandapani, Sivaraman; Palmer, Michelle; Schreiber, Stuart L.; Munoz, Benito (2011-12-01). "Identification of small-molecule inhibitors of Trypansoma cruzi replication". Bioorganic & Medicinal Chemistry Letters. 21 (23): 7197–7200. doi:10.1016/j.bmcl.2011.09.057. ISSN 1464-3405. PMID 22018462.
  34. ^ Kim, Sun Suk; Peng, Lee F.; Lin, Wenyu; Choe, Won-Hyeok; Sakamoto, Naoya; Kato, Nobuyuki; Ikeda, Masanori; Schreiber, Stuart L.; Chung, Raymond T. (January 2007). "A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication". Gastroenterology. 132 (1): 311–320. doi:10.1053/j.gastro.2006.10.032. ISSN 0016-5085. PMID 17241881.
  35. ^ Peng, Lee F.; Schaefer, Esperance A. K.; Maloof, Nicole; Skaff, Andrew; Berical, Andrew; Belon, Craig A.; Heck, Julie A.; Lin, Wenyu; Frick, David N.; Allen, Todd M.; Miziorko, Henry M.; Schreiber, Stuart L.; Chung, Raymond T. (2011-08-15). "Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase". The Journal of Infectious Diseases. 204 (4): 609–616. doi:10.1093/infdis/jir303. ISSN 1537-6613. PMC 3144167. PMID 21791663.
  36. ^ Radke, Joshua B.; Carey, Kimberly L.; Shaw, Subrata; Metkar, Shailesh R.; Mulrooney, Carol; Gale, Jennifer P.; Bittker, Joshua A.; Hilgraf, Robert; Comer, Eamon; Schreiber, Stuart L.; Virgin, Herbert W.; Perez, Jose R.; Sibley, L. David (2018-10-12). "High Throughput Screen Identifies Interferon γ-Dependent Inhibitors of Toxoplasma gondii Growth". ACS Infectious Diseases. 4 (10): 1499–1507. doi:10.1021/acsinfecdis.8b00135. ISSN 2373-8227. PMC 6200635. PMID 30058798.
  37. ^ Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ (October 1999). "Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen". Science. 286 (5441): 971–4. doi:10.1126/science.286.5441.971. PMID 10542155.
  38. ^ Viswanathan, Vasanthi S.; Ryan, Matthew J.; Dhruv, Harshil D.; Gill, Shubhroz; Eichhoff, Ossia M.; Seashore-Ludlow, Brinton; Kaffenberger, Samuel D.; Eaton, John K.; Shimada, Kenichi; Aguirre, Andrew J.; Viswanathan, Srinivas R.; Chattopadhyay, Shrikanta; Tamayo, Pablo; Yang, Wan Seok; Rees, Matthew G. (2017-07-27). "Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway". Nature. 547 (7664): 453–457. doi:10.1038/nature23007. ISSN 1476-4687. PMC 5667900. PMID 28678785.
  39. ^ Wainwright, Claire E.; Elborn, J. Stuart; Ramsey, Bonnie W.; Marigowda, Gautham; Huang, Xiaohong; Cipolli, Marco; Colombo, Carla; Davies, Jane C.; De Boeck, Kris (2015-07-16). "Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR". New England Journal of Medicine. 373 (3): 220–231. doi:10.1056/NEJMoa1409547. ISSN 0028-4793. PMC 4764353. PMID 25981758.
  40. ^ https://www.journals.elsevier.com/tetrahedron-letters/news/we-congratulate-the-award-winners-of-the-21st-nagoya-medal-o
  41. ^ "National Academy of Medicine Elects 85 New Members". National Academy of Medicine. 15 October 2018. Retrieved 2 May 2019.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Stuart_Schreiber&oldid=1224595130"